Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
On January 14, H.C. Wainwright analyst Mitchell Kapoor reaffirmed his optimistic outlook on Summit Therapeutics (NASDAQ:SMMT). He assigned a Buy rating to the stock with a $40 price target, resulting in an upside of nearly 143%. Copyright: dolgachov / 123RF Stock Photo Kapoor's rating comes at the back of the company's submission of Biologics License Application (BLA), relating to ivonescimab clinical program. He emphasized that in the short-run, stock performance will be driven by ivonescimab's survival data in the HARMONi-2 trial, and not so much by the regulatory filing mechanics in EGFR-mutated NSCLC. On January 13, Citizens also maintained its Market Outperform rating on Summit Therapeutics (NASDAQ:SMMT), with a $40 price target. The rating was based on the company's recent guidance on ivonescimab clinical program, and submission of its first Biologics License Application (BLA). Besides that, Citizens also highlighted the company's recent announcement to collaborate with
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $40.00 price target on the stock.MarketBeat
- Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
SMMT
Earnings
- 10/20/25 - Beat
SMMT
Sec Filings
- 1/29/26 - Form 8-K
- 1/12/26 - Form 4
- 1/12/26 - Form 8-K
- SMMT's page on the SEC website